Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Medha N. Munshi, MD, a geriatrician and endocrinologist at Beth Israel Deaconess Medical Center, has dedicated her career to ...

Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ...

These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...

Families want nurse or staff to monitor apps remotely in case of urgent alarms; schools cite shrinking budgets and internet ...

One of the most exciting developments in diabetes treatment is the use of new medications that help control blood sugar in ...

Patients trying to access technology for type one diabetes say they are not getting the support they need. Patients say ...

A three-year, $1.4m project aims to address inequities experienced by Māori and Pacific people with type 1 diabetes.

Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...